{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:00:50Z","timestamp":1786986050917,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014592","name":"Insulet Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet Med"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Automated insulin delivery (AID) systems continuously deliver insulin subcutaneously, reducing the burden of managing type 1 diabetes mellitus (T1D). However, there are limited data comparing different insulin delivery modalities, particularly regarding their impact on health\u2010related quality of life (HRQoL). This study aimed to quantify the disutility associated with conventional insulin delivery modalities and utility gains associated with wearable, on\u2010body, AID systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Health state vignettes representing different insulin delivery modalities were developed based on interviews with people with T1D alongside published literature and validated by experts. Utility values were elicited via the time trade\u2010off (TTO) method from the general population in the United Kingdom (UK) (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009110).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The lowest mean utility values were observed for tubed non\u2010AID systems (0.727), while the highest mean utility value was observed for tubeless systems with AID (0.909). The use of tubeless systems rather than tubed systems was associated with a significant increase in utility between + 0.082 and\u2009+ 0.086 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.005), and the use of AID was associated with a significant increase in utility of between +0.096 and +0.100 versus the corresponding alternatives (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0005). The use of a tubeless and AID system was associated with a significantly increased utility versus all other health states (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), indicating significantly higher HRQoL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study elicited utility values for health states representing insulin delivery modalities in T1D. Results suggested that tubeless and AID systems are associated with higher health state utility in T1D, indicating that people with T1D using such systems may experience improved HRQoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dme.70156","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:24:22Z","timestamp":1761816262000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of the added value of a tubeless pump: A time trade\u2010off (\n                    <scp>TTO<\/scp>\n                    ) study for utility elicitation of insulin delivery systems in type 1 diabetes mellitus (\n                    <scp>T1D<\/scp>\n                    )"],"prefix":"10.1111","volume":"42","author":[{"given":"Jackie","family":"Elliott","sequence":"first","affiliation":[{"name":"Sheffield Teaching Hospitals  Sheffield UK"},{"name":"University of Sheffield  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Hopley","sequence":"additional","affiliation":[{"name":"Insulet  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Riley","sequence":"additional","affiliation":[{"name":"Adelphi Values PROVE  Bollington Cheshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Dodd","sequence":"additional","affiliation":[{"name":"Adelphi Values PROVE  Bollington Cheshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Val","family":"Maranes","sequence":"additional","affiliation":[{"name":"Adelphi Values PROVE  Bollington Cheshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Tomas","sequence":"additional","affiliation":[{"name":"Insulet Canada Corporation  Oakville Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Littlewood","sequence":"additional","affiliation":[{"name":"Insulet  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"IDF.Type 1 diabetes. Accessed July 26 2024.https:\/\/www.idf.org\/aboutdiabetes\/type\u20101\u2010diabetes.html"},{"key":"e_1_2_11_3_1","unstructured":"LucierJWR.Type 1 Diabetes.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507713\/"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.27.1.9"},{"issue":"17","key":"e_1_2_11_5_1","first-page":"1","article-title":"Patient perspectives on quality of life with uncontrolled type 1 diabetes mellitus: a systematic review and qualitative meta\u2010synthesis","volume":"15","author":"Vanstone M","year":"2015","journal-title":"Ont Health Technol Assess Ser"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108281"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0417"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jan.13463"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2013.06.003"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds18-0091"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0830"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05391-w"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109858"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05744-z"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae088"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-010-0004-6"},{"key":"e_1_2_11_17_1","unstructured":"Insulet.About Omnipod 5\u00ae system.https:\/\/www.omnipod.com\/en\u2010gb\/what\u2010is\u2010omnipod\/omnipod\u20105"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-0685"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109998"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8867625"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.846262"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00718-8"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.10.007"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01144-4"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15087"},{"key":"e_1_2_11_26_1","unstructured":"National Institute for Clinical Excellence.Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.https:\/\/www.nice.org.uk\/guidance\/ta943"},{"key":"e_1_2_11_27_1","unstructured":"Scottish Health Technologies Group (SHTG).Closed\u2010Loop Systems and the Artificial Pancreas for the Management of T1DM.https:\/\/shtg.scot\/our\u2010advice\/closed\u2010loop\u2010systems\u2010and\u2010the\u2010artificial\u2010pancreas\u2010for\u2010type\u2010i\u2010diabetes\u2010mellitus\u2010t1dm\/"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.12.017"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-022-01470-w"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/prom.S322390"},{"key":"e_1_2_11_31_1","unstructured":"NICE.NICE health technology evaluations: the manual. Accessed August 6 2024.https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice\u2010health\u2010technology\u2010evaluations\u2010the\u2010manual\u2010pdf\u201072286779244741"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0404-1"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.12.160"},{"key":"e_1_2_11_34_1","unstructured":"RivelineJP RenardE WeinstockR et\u00a0al.Quality\u2010of\u2010Life Benefits for Adults Living with Type 1 Diabetes Using the Omnipod 5 System Compared with Insulin Pump Therapy: Results from a Randomized Controlled Trial.EASD.2024."},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-022-02029-2"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01682-8"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1536"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111123"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldq033"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.70156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:10:55Z","timestamp":1763565055000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.70156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/dme.70156"],"URL":"https:\/\/doi.org\/10.1111\/dme.70156","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"2025-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70156"}}